Linked Life Data

16762376

Source:http://linkedlifedata.com/resource/pubmed/id/16762376

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2006-8-21
pubmed:abstractText
Iloperidone is a novel atypical antipsychotic which acts as a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist. To compare iloperidone behaviorally to other known antipsychotics, we evaluated the drug in three pharmacological models and one developmental model of disrupted prepulse inhibition (PPI) in rats. Firstly, 0.5 mg/kg apomorphine induced PPI deficits that were prevented by pretreatment with iloperidone (1 and 3 mg/kg). Secondly, treatment with the N-methyl-D-aspartate (NMDA)-receptor antagonist phencyclidine (PCP) produced robust deficits in PPI. Both doses of iloperidone (1 and 3 mg/kg) prevented the PPI-disruptive effects of treatment with 1 mg/kg PCP. Thirdly, treatment with the alpha1-adrenoceptor agonist cirazoline (0.6 mg/kg) disrupted PPI, and produced a concurrent large increase in startle magnitude. A relatively low dose of iloperidone (0.3 mg/kg) prevented cirazoline-induced PPI deficits, independent of its effects on startle magnitude. Finally, iloperidone (1 mg/kg) did not reverse PPI deficits in the isolation-rearing model of schizophrenia. These results indicate that iloperidone exerts behavioral effects in pharmacological models of disrupted sensorimotor gating consistent with "atypical" antipsychotics, mediated by antagonism of dopaminergic and noradrenergic receptors. The absence of effect in isolation-reared rats may be due to the relatively small effect size of isolation rearing on PPI or dose of iloperidone.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0028-3908
pubmed:author
pubmed:issnType
Print
pubmed:volume
51
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
457-65
pubmed:dateRevised
2007-12-3
pubmed:meshHeading
pubmed-meshheading:16762376-Acoustic Stimulation, pubmed-meshheading:16762376-Adrenergic alpha-Agonists, pubmed-meshheading:16762376-Analysis of Variance, pubmed-meshheading:16762376-Animals, pubmed-meshheading:16762376-Antipsychotic Agents, pubmed-meshheading:16762376-Apomorphine, pubmed-meshheading:16762376-Behavior, Animal, pubmed-meshheading:16762376-Disease Models, Animal, pubmed-meshheading:16762376-Dopamine Agonists, pubmed-meshheading:16762376-Dose-Response Relationship, Drug, pubmed-meshheading:16762376-Dose-Response Relationship, Radiation, pubmed-meshheading:16762376-Drug Interactions, pubmed-meshheading:16762376-Excitatory Amino Acid Antagonists, pubmed-meshheading:16762376-Gait Disorders, Neurologic, pubmed-meshheading:16762376-Imidazoles, pubmed-meshheading:16762376-Isoxazoles, pubmed-meshheading:16762376-Male, pubmed-meshheading:16762376-Neural Inhibition, pubmed-meshheading:16762376-Phencyclidine, pubmed-meshheading:16762376-Piperidines, pubmed-meshheading:16762376-Rats, pubmed-meshheading:16762376-Rats, Sprague-Dawley, pubmed-meshheading:16762376-Startle Reaction
pubmed:year
2006
pubmed:articleTitle
Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats.
pubmed:affiliation
Molecular and Integrative Neurosciences Department, The Scripps Research Institute, La Jolla, CA, USA.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, U.S. Gov't, Non-P.H.S., Research Support, N.I.H., Extramural